Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept : a EUSTAR observational study

— Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept : a EUSTAR observational study

Joint involvement is common and disabling in systemic sclerosis (SSc). Of patients with SSc, 46–97% complain about joint stiffness or pain, and up to 30% exhibit inflammatory clinical signs.

RMDs are highly prevalent and significantly affect activity limitations and participation restrictions. More effort is needed to improve care and research in this field.